Aviso: para depositar documentos, por favor, inicia sesión e identifícate con tu cuenta de correo institucional de la UCM con el botón MI CUENTA UCM. No emplees la opción AUTENTICACIÓN CON CONTRASEÑA
 

Treatment of congenital coagulopathies, from biologic to biotechnological drugs: the relevance of gene editing (CRISPR/Cas)

Loading...
Thumbnail Image

Full text at PDC

Publication date

2023

Advisors (or tutors)

Editors

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier
Citations
Google Scholar

Citation

Abstract

Congenital coagulopathies have, throughout the history of medicine, been a focus of scientific study and of great interest as they constitute an alteration of one of the most important and conserved pathways of evolution. The first therapeutic strategies developed to address them were aimed at restoring the blood components lost during hemorrhage by administering whole blood or plasma. Later on, the use of cryoprecipitates was a significant breakthrough as it made it possible to decrease the volumes of blood infused. In the 1970′ and 80′, clotting factor concentrates became the treatment and, from the 1990's to the present day, recombinant factors –with increasingly longer half-lives– have taken over as the treatment of choice for certain coagulopathies in a seamless yet momentous transition from biological to biotechnological drugs. The beginning of this century, however, saw the emergence of new advanced (gene and cell) treatments, which are currently transforming the therapeutic landscape. The possibility to use cells and viruses as well as specific or bispecific antibodies as medicines is likely to spark a revolution in the world of pharmacology where therapies will be individualized and have long-term effects. Specifically, attention is nowadays focused on the development of gene editing strategies, chiefly those based on CRISPR/Cas technology. Rare coagulopathies such as hemophilia A and B, or even ultra-rare ones such as factor V deficiency, could be among those deriving the greatest benefit from these new developments.

Research Projects

Organizational Units

Journal Issue

Description

2023 Acuerdos Transformativos CRUE

Keywords

Collections